4.61
+0.105(+2.33%)
Currency In USD
| Previous Close | 4.5 |
| Open | 4.49 |
| Day High | 4.65 |
| Day Low | 4.48 |
| 52-Week High | 26.62 |
| 52-Week Low | 2.88 |
| Volume | 77,996 |
| Average Volume | 229,679 |
| Market Cap | 165.09M |
| PE | -0.68 |
| EPS | -6.81 |
| Moving Average 50 Days | 4.45 |
| Moving Average 200 Days | 6.34 |
| Change | 0.11 |
If you invested $1000 in BioAge Labs, Inc. (BIOA) since IPO date, it would be worth $251.5 as of August 22, 2025 at a share price of $4.605. Whereas If you bought $1000 worth of BioAge Labs, Inc. (BIOA) shares 6 months ago, it would be worth $1,058.62 as of August 22, 2025 at a share price of $4.605.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
GlobeNewswire Inc.
Aug 15, 2025 1:00 PM GMT
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial development planned in obesity; BGE-102 demonstrated robust weigh
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
GlobeNewswire Inc.
Jun 21, 2025 10:00 PM GMT
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for obesity and
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
GlobeNewswire Inc.
Jun 17, 2025 1:00 PM GMT
Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform insights into the biology of resilience across mul